CAMBRIDGE, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. NTGN, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, taking place November 9-11, 2018 in Washington, D.C.
Details for the oral presentation are as follows:
Presentation Title: The Personal Vaccine, NEO-PV-01 with anti-PD1, Induces Neoantigen-Specific De Novo Tumor-Related Immunity in Patients with Advanced Cancer
Presenter: Siwen Hu-Lieskovan, M.D., Ph.D., UCLA Medical Center
Session Title: Early Phase 1 Clinical Trials
Session Date & Time: Friday, November 9, 2018 from 2:15 - 3:40 p.m. ET
Details for the poster presentation relating to the NEO-PTC-01 program are as follows:
Presentation Title: In-Depth Characterization of Immune Responses Induced Against Patient-Specific Neoantigens using NEO-STIM™
Poster Hall Hours: Friday, November 9 from 8:00 a.m. - 8:00 p.m. ET; Saturday, November 10 from 8:00 a.m. - 8:30 p.m. ET
Poster Number: P169
Location: Hall E
Details for the poster presentations relating to the NEO-PV-01 program are as follows:
Presentation Title: Comprehensive Immune and Molecular Analysis of a Cohort of Non-Small Cell Lung Cancer (NSCLC) Patients Treated with a Personal Neoantigen Vaccine, NEO-PV-01, in Combination with Anti-PD1
Poster Hall Hours: Friday, November 9 from 8:00 a.m. - 8:00 p.m. ET; Saturday, November 10 from 8:00 a.m. - 8:30 p.m. ET
Poster Number: P49
Location: Hall E
Presentation Title: An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
Poster Hall Hours: Friday, November 9 from 8:00 a.m. - 8:00 p.m. ET; Saturday, November 10 from 8:00 a.m. - 8:30 p.m. ET
Poster Number: P314
Location: Hall E
Presentation Title: An Open-Label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX-005M) or Ipilimumab with Nivolumab in Patients with Advanced or Metastatic Melanoma
Poster Hall Hours: Friday, November 9 from 8:00 a.m. - 8:00 p.m. ET; Saturday, November 10 from 8:00 a.m. - 8:30 p.m. ET
Poster Number: P307
Location: Hall E
About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer. For more information, please visit www.neontherapeutics.com.
Media Contact:
Stephanie Simon, Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333
Investor Contact:
Will O'Connor, Stern Investor Relations
will@sternir.com
212-362-1200
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.